POSEIDA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.71 USD | -7.19% |
|
-2.17% | -19.35% |
| 05-02 | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
| 05-01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
| Sales 2024 * | 52.92M 4.24B | Sales 2025 * | 27.5M 2.2B | Capitalization | 263M 21.06B |
|---|---|---|---|---|---|
| Net income 2024 * | -179M -14.35B | Net income 2025 * | -225M -18.04B | EV / Sales 2024 * | 4.96 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.55 x |
| P/E ratio 2024 * |
-1.61
x | P/E ratio 2025 * |
-1.52
x | Employees | 330 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.23% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -7.19% | ||
| 1 week | -2.17% | ||
| Current month | +11.98% | ||
| 1 month | -8.75% | ||
| 3 months | -19.82% | ||
| 6 months | +18.86% | ||
| Current year | -19.35% |
1 week
2.68
3.00
1 month
1.873.00
Current year
1.874.27
1 year
1.544.27
3 years
1.5411.10
5 years
1.5417.62
10 years
1.5417.62
| Managers | Title | Age | Since |
|---|---|---|---|
Kristin Yarema
CEO | Chief Executive Officer | 53 | 31/03/23 |
Johanna Mylet
DFI | Director of Finance/CFO | 37 | 31/05/15 |
Mark Gergen
CHM | Chairman | 61 | 31/01/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marcea Lloyd
BRD | Director/Board Member | 75 | 31/12/18 |
Cynthia Collins
BRD | Director/Board Member | 65 | 22/07/21 |
Mark Gergen
CHM | Chairman | 61 | 31/01/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.87% | 2 M€ | -25.75% | ||
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 2.71 | -7.19% | 359,616 |
| 07/05/24 | 2.92 | +3.18% | 385,765 |
| 06/05/24 | 2.83 | -1.39% | 546,658 |
| 03/05/24 | 2.87 | +2.87% | 549,987 |
| 02/05/24 | 2.79 | +0.72% | 1,355,913 |
Delayed Quote Nasdaq, May 08, 2024 at 09:00 pm
More quotes
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.71
USD
Average target price
14
USD
Spread / Average Target
+416.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.35% | 263M | |
| +2.93% | 108B | |
| -2.13% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- PSTX Stock
